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Abstract
Background. Statin use in renal transplantation has been
associated with a lower risk of patient death but not with
an improvement of graft functional survival. The aim of
this study is to evaluate the effect of statin use in graft sur-
vival, death-censored graft survival and patient survival us-
ing the data recorded on the Spanish Late Allograft
Dysfunction Study Group.
Patients and methods. Patients receiving a renal allograft
in Spain in 1990, 1994, 1998 and 2002 were considered.
Since the mean follow-up in the 2002 cohort was 3 years,
statin use was analysed considering its introduction during
the first year or during the initial 2 years after transplanta-
tion. Univariate and multivariate Cox regression analyses
with a propensity score for statin use were employed to an-
alyse graft survival, death-censored graft survival and pa-
tient survival.
Results. In the 4682 evaluated patients, the early statin use
after transplantation significantly increased from 1990 to
2002 (12.7%, 27.9%, 47.7% and 53.0%, P < 0.001). Statin
use during the first year was not associated with graft or
patient survival. Statin use during the initial 2 years was
associated with a lower risk of graft failure (relative risk
[RR] = 0.741 and 95% confidence interval [CI] = 0.635–
0.866, P < 0.001) and patient death (RR = 0.806 and 95%
CI = 0.656–0.989, P = 0.039). Death-censored graft survival
was not associated with statin use during the initial 2 years.
Conclusion. The early introduction of statin treatment af-
ter transplantation is associated with a significant decrease
in late graft failure due to a risk reduction in patient death.
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Introduction
Statins were introduced in clinical practice more than two
decades ago to treat dyslipidaemia, especially hypercholes-
terolaemia with increased low-density lipoprotein (LDL)-
cholesterol levels. Its efficacy in the general population
with preserved renal function for primary and secondary
prevention of cardiovascular events has been well estab-
lished in different clinical trials and further confirmed in
different meta-analyses [1,2]. For this reason, statins have
been widely introduced in clinical practice to treat hyperch-
olesterolaemia in patients with different co-morbidities, for
example patients with chronic renal failure, despite its util-
ity not having been evaluated in clinical trials in these spe-
cific groups of patients.
Patients with chronic kidney disease as well as patients
with end-stage renal disease either treated with dialysis or
receiving a kidney transplant have an increased cardiovas-
cular risk that accounts for more than 50% of the overall
mortality [3,4]. In patients with end-stage renal disease on
haemodialysis, prospective randomized clinical trials test-
ing the potential benefits of statin treatment have led to
contradictory results [5–7]. In the setting of renal trans-
plantation, only one large prospective, randomized, place-
bo-controlled study has been conducted to evaluate
fluvastatin treatment: the ALERT trial [8]. In this study,
the primary efficacy variable was defined as cardiac death,
non-fatal myocardial infarction and/or a coronary interven-
tion procedure. Despite a significant decrease in the num-
ber of cardiac deaths and non-fatal myocardial infarctions,
the 13% reduction in the primary efficacy end point did
not reach statistical significance. Nevertheless, the exten-
sion of the ALERT study for two additional years showed
a significant reduction in major adverse cardiac events,
supporting that the benefits of fluvastatin in renal trans-
plant recipients are comparable to other patient groups [9].
On the other hand, the post hoc analysis of the ALERT
study failed to reveal a beneficial effect of fluvastatin
on renal outcome. However, in the general population,
there is evidence linking dyslipidaemia and its treatment
with reduced renal function decline [10–12]. It is important
toremarkthatintheALERTtrial, patientswererandomized
at a mean follow-up time of 4 years, and it could be argued
that at this time renal lesions may be too advanced. In renal
transplantation, clinical trials with small sample size and
short periods of follow-up have suggested that statins may
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pathy [14] when they are introduced just after transplanta-
tion.However,informationaboutthelong-termevolutionof
renal function or death-censored graft survival is lacking.
Thus, the potential benefit of statins on graft survival will
not be evaluated until large, prospective,multicentre, place-
bo-controlled studies are conducted from the time of trans-
plantation. Since such studies are difficult to perform, renal
transplant registries may provide valuable information on
the potential beneficial effect of statins on graft outcome.
In the present study, we evaluate the effect of statin use
in patient survival, graft survival and death-censored graft
survival using the data recorded by the Spanish Late Allo-
graft Dysfunction Study Group.
Materials and methods
Study design
For the present study, patients receiving a renal allograft in Spain in 1990,
1994, 1998 and 2002 were considered. Only adult transplant centres were
invited to participate, and only adult patients (≥18 years) receiving a sin-
gle kidney transplant that was functioning at the end of the first year of
follow-up were considered. Patients receiving multi-organic or double
transplants were excluded. Last follow-up was on 31 December 2005.
Clinical variables
The following variables were evaluated in each patient at the time of sur-
gery: source of the organ (living or deceased donor), donation before or
after cardiac death, cause of donor death (trauma, stroke or others), age
and gender of the donor and the recipient, height and weight of the recip-
ient,presenceofhepatitisBsurfaceantigenandhepatitisCvirusantibodies
in the donor and the recipient, aetiology of end-stage renal disease, time on
dialysis, last panel reactive antibodies (PRA), number of human leukocyte
antigen (HLA) mismatches and cold ischaemia and re-anastomosis times.
After surgery, the presence of delayed graft function and acute re-
jection were recorded. Immunosuppressive treatment at 1 year was de-
scribed on an intention-to-treat basis and classified in four major groups:
(i) cyclosporine-based not associated with mycophenolate mofetil,
(ii) cyclosporine-based associated with mycophenolate mofetil,
(iii) tacrolimus-based treatment, and (iv) other treatments.
At 3 months and yearly thereafter, serum creatinine, 24 h proteinuria,
serum fasting glucose and serum cholesterol and triglycerides were re-
corded. At the same time periods, treatment with statins was recorded
as a dichotomous variable. Patients treated with statins either at 3 months
or 1 year were classified as statin users during the first year. Similarly,
patients receiving statins either at 3 months, 1 year or 2 years were clas-
sified as statin users during the first 2 years. Additionally, treatment with
antihypertensive drugs including angiotensin-converting enzymes inhibi-
tors (ACEi) or angiotensin II receptor blockers (ARB) were also recorded.
Definition of variables
Delayed graft function was defined as haemodialysis requirements during
the first week after surgery, once accelerated or once hyperacute rejection,
vascular complications and urinary tract obstruction were ruled out. The
diagnosis of acute rejection was defined at each centre based on clinical
and/or histological data.
The ethical committee of the Hospital Universitari de Bellvitge ap-
proved this study. Medical records review was performed according to
Spanish law with reference to clinical data confidentiality protection. A
blinded code was assigned to each participating hospital in order to take
into consideration the centre effect.
Statistics
Descriptive results are expressed as frequencies and percentages for cat-
egorical variables and mean ± standard deviation for normally distributed
continuous variables. These variables were compared in statin users and
non-users by means of chi-square test for categorical data, Wilcoxon T-
test for ordinal or not normally distributed continuous data and Students’
T-test for continuous normally distributed data.
Kaplan–Meier analysis was used to estimate overall graft survival,
death-censored graft survival and patient survival. Log rank test was em-
ployed to compare differences between groups.
Cox regression analysis adjusting for year of transplantation was em-
ployed to analyse the association between statin use and graft survival,
death-censored graft survival and patient survival. Multivariate backward
Cox regression analysis was performed to further evaluate the indepen-
dent association of statin use and survival. In order to take into consider-
ation confounding by indication, a propensity score of statin use was
calculated and introduced in all multivariate analysis. The propensity
score was calculated by a logistic regression considering all variables as-
sociated with statin use. This analysis provides a probability score of be-
ing treated with statins for each patient, and this score (ranging from 0 to
1) was divided in quartiles and considered in the multivariate Cox regres-
sion analysis.
Statin use was analysed considering two different settings in order to
take into account the timing of the introduction of statin treatment: intro-
duction of statins during the first year after transplantation and introduc-
tion of statins during the initial 2 years after transplantation. Since the
mean follow-up in the 2002 cohort was 3 years, no attempts were made
to evaluate introduction of statins after 3 years or later.
For all analysis, a two-sided P-value <0.05 was considered significant.
Results
Patients
A total of 4842 patients were included in the Spanish Late
Allograft Dysfunction Study Group, but information about
statin use was only available in 4682 patients (96.6%). The
number of patients in the 1990, 1994, 1998 and 2002 co-
horts were 809, 1083, 1507 and 1283, respectively.
In the 1990 and 1994 cohorts, statins were used margin-
ally during the initial years after transplantation, while in
the 1998 and 2002 cohorts, a significant proportion of pa-
tients were treated with statins during the initial years af-
ter transplantation. However, since the follow-up period
was longer in the 1990 and 1994 cohorts, at the end of
follow-up the proportion of patients receiving statins was
similar in the different cohorts (Figure 1). Demographic
characteristics of patients and clinical data after transplan-
Fig. 1. Percentage of patients treated with statins during the first and
second years and at the end of follow-up.
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in Table 1.
Survival and statin use during the first yearafter transplant
During the first year of follow-up, a total of 1440 patients
(30.7%) were treated with statins. Graft survival was
50.2% for patientsnot receiving statinsand 55.6% for statin
users (P<0.001). However, Cox regression analysis adjust-
ingfortheyearoftransplantdidnotconfirmthisassociation
(relative risk [RR] for statin users 0.901, 95% confidence
interval [CI] 0.757–1.064; P = 0.210).
Death-censored graft survival was 62.6% for patients
not receiving statins and 64.3% for statin users (P =
0.005). Once again, Cox regression analysis adjusting for
the year of transplant showed that there was no association
between statin use and death-censored graft survival (RR
1.909, 95% CI 0.741–1.112; P = 0.349).
Finally, patient survival was 65.4% for patients not
receiving statins and 78.4% for statin users (P = 0.014),
but once more, Cox regression analysis adjusting for the
year of transplant showed that there was no association be-
tween statin use during the first year and patient survival
(RR 0.869, 95% CI 0.689–1.087; P = 0.226).
Table 1. Patient characteristics according to statin use at 2 years
Variable No statin use Statin use P-value
N 2879 1803
Donor age (years) 40.1 ± 16.9 44.8 ± 16.5 < 0.001
Donor gender (% male) 65.5 63.4 ns
Patient age (years) 44.8 ± 13.5 49.2 ± 12.2 < 0.001
Patient gender (% male) 64.6 60.7 < 0.001
Pre-transplant diabetes (%) 4.6 7.3 < 0.001
Hepatitis C virus (% positive) 17.9 8.1 < 0.001
Weight at transplant (kg) 65.5 ± 12.2 67.8 ± 12.3 < 0.001
HLA DR mm (0/1/2) 36.8 / 54.5 / 8.7 30.5 / 60.0 / 9.4
Baseline immunosupression (%)
CsA without MMF 55.7 32.6
CsA with MMF 17.2 32.7
Tacrolimus 18.9 24.0
Other 8.2 10.7 < 0.001
Delayed graft function (%) 30.0 31.7 ns
Acute rejection (%) 31.3 23.2 < 0.001
Diabetes at 1 year (%) 4.1% 7.8% < 0.001
Creatinine 1 year (mg%) 1.6 ± 0.7 1.6 ± 0.6 ns
Proteinuria (g/day) 0.3 ± 0.8 0.4 ± 0.9 ns
Cholesterol 1 year (mg%) 212 ± 43 230 ± 49 < 0.001
Triglycerides 1 year (mg%) 140 ± 64 164 ± 81 < 0.001
HLA DR mm, number of mismatches in DR loci; CsA, cylosporine A; MMF, mycophenolate mofetil.
Fig. 2. Graft survival according to statin treatment during the initial 2 years after transplantation (P < 0.001, log rank test).
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Duringtheinitial2yearsafter transplantation,1803patients
(38.5%) received treatment with statins, and graft survival
was 55.6% for patients treated with statins and 50.2% for
patients not receiving statins, P < 0.001 (Figure 2). Cox re-
gression analysis adjusting for the year of transplantation
confirmed a lower graft survival for patients not receiving
statins (RR 0.837, 95% CI 0.720–0.974; P = 0.022). Multi-
variate Cox regression analysis with a propensity score for
statin use confirmed that statin use during the initial 2 years
after transplantation is an independent predictor of graft
survival (Table 2).
Death-censored graft survival was 65.1% for patients
treated with statins and 62.5% for patients not receiving
statins, P = 0.001. Cox regression analysis adjusting for
the year of transplantation showed that there was no asso-
ciation between death-censored graft survival and statin
use (RR 0.869, 95% CI 0.724–1.042; P = 0.125).
Patient survival was 74.6% for patients treated with sta-
tins and 64.7% for patients not receiving statins during the
initial 2 years, P = 0.003 (Figure 3). Cox regression anal-
ysis adjusting for the year of transplantation showed a
trend for higher graft survival for patients receiving statins
(RR 0.820, 95% confidence interval 0.671–1.010; P =
0.059). Multivariate Cox regression analysis with a pro-
pensity score for statin use showed that statin treatment
during the initial 2 years after transplantation was an inde-
pendent predictor of patient death (Table 3).
Discussion
In this retrospective observational study evaluating the po-
tential benefits of early introduction of statins after trans-
plantation, we observed that statin treatment during the
initial 2 years is associated with a longer renal allograft
survival, but we failed to detect a significant modification
on death-censored graft survival. Moreover, despite the
Table 2. Multivariate Cox regression analysis of graft survival with a propensity score for statin use at 2 years adjusted for the year of transplant
Variable Relative risk 95% confidence interval P-value
Donor age > 60 years 1.396 1.159–1.681 < 0.001
Patient age > 60 years 1.686 1.400–2.031 < 0.001
Re-transplant 1.441 1.203–1.726 < 0.001
Pre-transplant diabetes 1.912 1.424–2.571 < 0.001
Acute rejection 1.226 1.059–1.418 0.006
3 months creatinine (mg%) 1.857 1.706–2.022 < 0.001
Delta creatinine 3 m-1 y 2.084 1.932–2.247 < 0.001
3 months proteinuria (g/day) 1.218 1.148–1.292 < 0.001
Delta proteinuria 3 m-1 y 1.256 1.191–1.333 < 0.001
3 months triglycerides (mg%) 1.002 1.001–1.003 < 0.001
Statin use at 2 years 0.741 0.635–0.866 < 0.001
Fig. 3. Patient survival according to statin treatment during the initial 2 years after transplantation (P = 0.003, log rank test).
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tient survival was on the verge of significance, multivariate
analysis confirmed a 20% risk reduction in death in pa-
tients receiving statins. Thus, our results showed that the
benefit of statins on graft outcome is mainly due to an im-
provement of patient survival, but we failed to detect a
beneficial effect on kidney functional survival. This result
is in agreement with the ALERT study, a prospective ran-
domized trial of statin use in renal transplantation [7,8]. In
the same way, the analysis of the Austrian registry showed
that statin use was associated with a 36% reduction in all-
cause mortality, while risk reduction in death-censored
graft survival was in the limit of significance (76% for sta-
tin users and 70% for non-users; P = 0.055), once more
pointing out that the benefit of statins in renal transplant
population is mainly due to an improvement in patient sur-
vival [15]. Our cohort of patients was rather different from
the Austrian cohort since in the Austrian study all patients
transplanted between 1990 and 2003 were considered,
while we only evaluated patients transplanted in 1990,
1994, 1998 and 2002. It is important to take into consid-
eration this difference since it has determined a different
statistical approach. The Austrian cohort was analysed
considering statin use as a time-dependent variable which
may be the most appropriate approach to evaluate the ret-
rospective use of a treatment that is introduced at different
time points of follow-up. We were not able to deal with
statins as a time-dependent variable since follow-up in
the 2002 cohort was too short.
Despite the above-mentioned limitation, we explored
whether statin introduction during the first year or the
two initial years implied a different outcome since it has
been claimed that the maximal benefit may be obtained
when statins are introduced as early as possible. In our
study, we failed to observe a significant reduction in pa-
tient or graft survival when the impact of statin introduc-
tion during the first year after transplantation was
analysed. In this evaluation, the number of patients using
statins was rather low in the cohorts of patients trans-
planted in 1990 and 1994, while time of follow-up was
only 2 years in patients transplanted in 2002. Thus, it
may be argued that these epidemiological characteristics
of our cohort of patients limited the possibility to detect
a risk reduction in this very early intervention. However,
the analysis of introduction of statins during the initial
2 years after transplantation yielded positive results. In
this second analysis, the number of patients using statins
in the 1990 and 1994 cohorts was twice that in the previ-
ous analysis, and it has allowed us to increase our statis-
tical power to detect the risk reduction associated with
statin use.
On the other hand, between 1990 and 2002, demograph-
ic characteristics of donor and recipients as well as immu-
nosuppression have significantly changed. In the 1998 and
2002 cohorts, older kidney donors were transplanted into
older transplant recipients, and the introduction of myco-
phenolate mofetil and tacrolimus yielded a lower acute re-
jection rate. Multivariate analysis showed that the
association between statins and survival was independent
of these major determinants of graft and patient survival.
One important limitation of retrospective studies about
the impact of an intervention on outcome is confounding
by indication. In order to overcome this potential bias, it
has been proposed to use propensity scores to balance
baseline covariates between exposure groups [16]. Of
course, this approach does not take into consideration un-
measured characteristics or confounders. We have done
C o xm u l t i v a r i a t er e g r e s s i o na n a l y s i sw i t ha n dw i t h o u t
the propensity scores, and results were very similar with
minimal modifications in the risks estimates (data not
shown). Despite it being proposed that propensity scores
are especially useful to analyse populations with a low
number of events or a large number of confounders [16],
we prefer to show our results using propensity scores since
there were important differences in the population receiv-
ing and not receiving statins.
We have failed to show a reduction in death-censored
graft failure in statin-treated patients. This benefit has been
demonstrated in the general population [10–12], but it has
not been confirmed in renal transplant patients [8]. In our
study, intervention with statins was done during the first or
second year after transplantation, and the number of pa-
tients, as well as the number of events, were sufficiently
large to detect a significant benefit. However, there was
a minimal difference in death-censored graft survival
(65.1% for statin users at 2 years and 62.5% for non-users).
Moreover,sincewedidnotfindanyinteractionbetweensta-
tin use and year of transplant, it would not be expected a
significant benefit in any cohort. Thus, our results agree
with previous studies failing to demonstrate that statin use
is associated with a risk reduction in graft functional deteri-
oration.However,our resultsdonotdenythepossibilitythat
statin use may be beneficial in high-risk patients, for exam-
ple, patients with significant proteinuria.
In summary, we showed in a large cohort of patients
transplanted in Spain between 1990 and 2002 that the early
introduction of statin treatment is associated with a signif-
icant decrease in late graft failure due to patient death.
Table 3. Multivariate Cox regression analysis of patient survival with a propensity score for statin use at 2 years adjusted for the year of transplant
Variable Relative risk 95% confidence interval P-value
Patient age >60 years 2.514 2.040–3.097 < 0.001
Hepatitis C virus positive 1.921 1.415–2.609 < 0.001
3 months creatinine (mg%) 1.545 1.365–1.749 < 0.001
Delta creatinine 3 m-1 y 1.391 1.207–1.604 < 0.001
Delta proteinuria 3 m-1 y 1.154 1.052–1.266 0.002
Statin use at 2 years 0.806 0.656–0.989 0.039
Delta creatinine between 3 months and 1 year (3 m-1y) was calculated as the difference between 1 year and 2 months serum creatinine.
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